MX2021013488A - Formulaciones liquidas de dosis oral de metilnaltrexona. - Google Patents
Formulaciones liquidas de dosis oral de metilnaltrexona.Info
- Publication number
- MX2021013488A MX2021013488A MX2021013488A MX2021013488A MX2021013488A MX 2021013488 A MX2021013488 A MX 2021013488A MX 2021013488 A MX2021013488 A MX 2021013488A MX 2021013488 A MX2021013488 A MX 2021013488A MX 2021013488 A MX2021013488 A MX 2021013488A
- Authority
- MX
- Mexico
- Prior art keywords
- methylnaltrexone
- oral dosage
- liquid oral
- dosage formulations
- docusate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962844613P | 2019-05-07 | 2019-05-07 | |
| US202063010528P | 2020-04-15 | 2020-04-15 | |
| PCT/EP2020/062794 WO2020225395A1 (en) | 2019-05-07 | 2020-05-07 | Liquid oral dosage formulations of methylnaltrexone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021013488A true MX2021013488A (es) | 2021-12-10 |
Family
ID=70802839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021013488A MX2021013488A (es) | 2019-05-07 | 2020-05-07 | Formulaciones liquidas de dosis oral de metilnaltrexona. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220096461A1 (enExample) |
| EP (1) | EP3965731A1 (enExample) |
| JP (1) | JP7692366B2 (enExample) |
| CN (1) | CN113747882A (enExample) |
| AU (1) | AU2020268767B8 (enExample) |
| BR (1) | BR112021022194A2 (enExample) |
| CA (1) | CA3137488C (enExample) |
| MX (1) | MX2021013488A (enExample) |
| WO (1) | WO2020225395A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI489984B (zh) | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
| WO2021224138A1 (en) | 2020-05-02 | 2021-11-11 | Bausch Health Ireland Limited | Methods of reducing mortality risk in subjects suffering from an underlying disease or condition by administration of methylnaltrexone |
| AU2022248850A1 (en) * | 2021-03-27 | 2023-11-09 | TRx Biosciences Limited | Compositions having improved bioavailability of therapeutics |
| WO2025177181A1 (en) * | 2024-02-19 | 2025-08-28 | Nanoprime Labs Corp | Self-assembling microemulsions carrying nutraceuticals and methods for use thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4518433A (en) | 1982-11-08 | 1985-05-21 | Fmc Corporation | Enteric coating for pharmaceutical dosage forms |
| US4719215A (en) | 1986-03-07 | 1988-01-12 | University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
| US4861781A (en) | 1986-03-07 | 1989-08-29 | The University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
| US4816259A (en) | 1987-02-12 | 1989-03-28 | Chase Chemical Company, L.P. | Process for coating gelatin capsules |
| US5102887A (en) | 1989-02-17 | 1992-04-07 | Arch Development Corporation | Method for reducing emesis and nausea induced by the administration of an emesis causing agent |
| US5330759A (en) | 1992-08-26 | 1994-07-19 | Sterling Winthrop Inc. | Enteric coated soft capsules and method of preparation thereof |
| DE19651551C2 (de) | 1996-12-11 | 2000-02-03 | Klinge Co Chem Pharm Fab | Opioidantagonisthaltige galenische Formulierung |
| US5972954A (en) | 1997-11-03 | 1999-10-26 | Arch Development Corporation | Use of methylnaltrexone and related compounds |
| US6559158B1 (en) | 1997-11-03 | 2003-05-06 | Ur Labs, Inc. | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects |
| US6274591B1 (en) | 1997-11-03 | 2001-08-14 | Joseph F. Foss | Use of methylnaltrexone and related compounds |
| CN1688294A (zh) | 2002-10-01 | 2005-10-26 | 旗帜药物胶囊公司 | 用于制备软胶囊壁的肠溶组合物 |
| MXPA05010821A (es) | 2003-04-08 | 2006-03-30 | Progenics Pharm Inc | Terapia de combinacion para constipacion que comprende un laxante y un antagonista opioide periferico. |
| JP2006522817A (ja) | 2003-04-08 | 2006-10-05 | プロジェニックス ファーマシューティカルズ，インコーポレーテッド | 過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用 |
| US8946262B2 (en) | 2003-12-04 | 2015-02-03 | Adolor Corporation | Methods of preventing and treating gastrointestinal dysfunction |
| AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
| TWI605814B (zh) * | 2010-03-11 | 2017-11-21 | 惠氏有限責任公司 | 甲基拿淬松（ｍｅｔｈｙｌｎａｌｔｒｅｘｏｎｅ）之口服製劑及親脂性鹽 |
| JP6397813B2 (ja) | 2012-05-02 | 2018-09-26 | キャプシュゲル・ベルジウム・エヌ・ヴィ | ヒドロキシプロピルメチルセルロースアセテートスクシネート（ｈｐｍｃａｓ）の水性分散液 |
| US10485798B2 (en) * | 2012-08-22 | 2019-11-26 | Aptapharma Inc. | Methylnaltrexone nasal formulations, methods of making, and use thereof |
| EP3206491B1 (en) * | 2014-10-17 | 2019-11-27 | Salix Pharmaceuticals, Inc. | Use of methylnaltrexone to attenuate tumor progression |
-
2020
- 2020-05-07 WO PCT/EP2020/062794 patent/WO2020225395A1/en not_active Ceased
- 2020-05-07 BR BR112021022194A patent/BR112021022194A2/pt unknown
- 2020-05-07 CA CA3137488A patent/CA3137488C/en active Active
- 2020-05-07 EP EP20727590.0A patent/EP3965731A1/en active Pending
- 2020-05-07 MX MX2021013488A patent/MX2021013488A/es unknown
- 2020-05-07 JP JP2021565869A patent/JP7692366B2/ja active Active
- 2020-05-07 CN CN202080033965.4A patent/CN113747882A/zh active Pending
- 2020-05-07 AU AU2020268767A patent/AU2020268767B8/en not_active Expired - Fee Related
-
2021
- 2021-10-06 US US17/495,413 patent/US20220096461A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020268767B1 (en) | 2025-07-17 |
| CA3137488C (en) | 2023-10-31 |
| CN113747882A (zh) | 2021-12-03 |
| WO2020225395A1 (en) | 2020-11-12 |
| JP7692366B2 (ja) | 2025-06-13 |
| AU2020268767A1 (en) | 2021-10-28 |
| AU2020268767B8 (en) | 2025-08-07 |
| JP2022531685A (ja) | 2022-07-08 |
| BR112021022194A2 (pt) | 2021-12-28 |
| EP3965731A1 (en) | 2022-03-16 |
| CA3137488A1 (en) | 2020-11-12 |
| US20220096461A1 (en) | 2022-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501774A1 (en) | Compositions comprising a combination of an anti-pd-1 antibody and another antibody | |
| CY1124914T1 (el) | Στερεες φαρμακευτικες συνθεσεις που περιεχουν αναστολεα ιντεγκρασης | |
| WO2018022815A3 (en) | Transdermal formulation and delivery method of low solubility or unstable unionized neutral drugs by in situ salt-to-neutral drug conversion of salt drug | |
| NZ720906A (en) | Orally disintegrating solid dosage unit containing an estetrol component | |
| MX356111B (es) | Composiciones farmaceuticas disuasorias de abuso, de liberacion inmediata. | |
| MX344787B (es) | Composiciones que contienen berberina o analogos de la misma para tratar rosacea o trastornos de la piel relacionados con enrojecimiento de la cara. | |
| MX390145B (es) | Formulaciones para la administracion de eflornitina | |
| MX2020012989A (es) | Agente terapeutico para la fibrosis. | |
| BR112021022194A2 (pt) | Formulações líquidas para dosagem oral de metilnaltrexona | |
| MX382580B (es) | Formulaciones de liberación inmediata disuasivas de abuso que comprenden polisacáridos no celulósicos. | |
| PH12019500154A1 (en) | Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof | |
| AU2017276588A1 (en) | Physiologically balanced injectable formulations of fosnetupitant | |
| WO2020260956A3 (en) | Self-emulsifying cannabidiol formulations | |
| MX2010004556A (es) | Formulacion farmaceutica de acido clavulanico. | |
| MX2017006168A (es) | Composiciones. | |
| MX2021004553A (es) | Composiciones farmaceuticas y metodos para fabricar formulaciones de dosificacion solidas bajo demanda. | |
| CR20220453A (es) | Composiciones de palmitato de vitamina a, procesos para su preparación, usos y métodos que las componen | |
| PH12020551547A1 (en) | Pharmaceutical preparation | |
| PH12019501260A1 (en) | A fast disintegrating pharmaceutical composition | |
| MX367121B (es) | Composición sólida estable de inmunosupresores. | |
| MD20160131A2 (ro) | Compus de tiacumicină şi regim de tratament asociat | |
| MX2022004464A (es) | Composicion farmaceutica que comprende un inhibidor de la bomba de protones y un antiacido. | |
| PH12020550597A1 (en) | Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt | |
| UA109243U (uk) | Тверда лікарська форма, що містить інгібітор віл протеази | |
| MA47185A (fr) | Compositions auto-émulsifiantes d'ingrédients pharmaceutiques actifs peu ionisables ou faiblement ionisables |